Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 142 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diflucan (fluconazole) Clear all
Completed Phase 1 Interventional

Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO)

NCT01169402
View directory record Official record
Conditions
Cardiopulmonary Arrest, Fungal Infection
Interventions
Fluconazole
Drug
Lead sponsor
Michael Cohen-Wolkowiez
Other
Eligibility
Up to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)

NCT00075803
View directory record Official record
Conditions
Lymphoma, Infection, Leukemia
Interventions
Fluconazole, Voriconazole
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 2, 2026, 7:02 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235

NCT04464577
View directory record Official record
Conditions
Healthy Participants
Interventions
Fluconazole, Bupropion, Itraconazole, BMS-986235
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

NCT04871724
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Fluconazole
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Not applicable Interventional

Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00002076
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Oakland, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

NCT03253094
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Fluconazole, SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Olomorasib (LY3537982) in Healthy Participants

NCT07439250
View directory record Official record
Conditions
Healthy
Interventions
Olomorasib, Fluconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

NCT00001017
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed No phase listed Observational

Neurodevelopmental Outcomes and Fluconazole Prophylaxis

NCT00975949
View directory record Official record
Conditions
Neurodevelopmental Outcomes
Interventions
Survey
Other
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 10 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

NCT04702464
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fedratinib, Fluconazole
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

NCT00885703
View directory record Official record
Conditions
Cryptococcal Meningitis, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

NCT00002122
View directory record Official record
Conditions
Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin, Rifabutin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

NCT00002394
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Terbinafine hydrochloride
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Fort Lauderdale, Florida • Fort Myers, Florida • Tamarac, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 7:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

NCT06129734
View directory record Official record
Conditions
Myeloid Malignancy, Acute Myeloid Leukemia
Interventions
Venetoclax, Decitabine
Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 2, 2026, 7:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA), Intensive chemotherapy with 7 + 3
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Newport Beach, California • Palo Alto, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

NCT02733432
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 2, 2026, 7:02 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults

NCT07395024
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Setidegrasib, Fluconazole, Carbamazepine, Itraconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

NCT02971007
View directory record Official record
Conditions
Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions
Oral Encochleated Amphotericin B (CAMB), Fluconazole
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 2, 2026, 7:02 AM EDT
Terminated Phase 1 Interventional

Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease

NCT01950507
View directory record Official record
Conditions
Stem Cell Transplantation, Graft vs Host Disease
Interventions
Budesonide, Fluconazole, Voriconazole, Micafungin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
13 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613
View directory record Official record
Conditions
Drug Interactions
Interventions
CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

A Study Of Diflucan In Children With Ringworm Of The Scalp

NCT00645242
View directory record Official record
Conditions
Tinea Capitis
Interventions
fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 12 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
28
States / cities
Montgomery, Alabama • Little Rock, Arkansas • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

NCT00734539
View directory record Official record
Conditions
Candidiasis
Interventions
fluconazole, placebo
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
2 Days to 5 Days
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
33
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 2, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

NCT00002446
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Posaconazole, Fluconazole
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
17
States / cities
Berkeley, California • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 7:02 AM EDT